ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 151 filers reported holding ESPERION THERAPEUTICS INC NE in Q3 2022. The put-call ratio across all filers is 0.22 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $21,280 | -10.7% | 21,714 | +26.7% | 0.00% | – |
| Q2 2023 | $23,819 | +4.5% | 17,136 | +19.5% | 0.00% | – |
| Q1 2023 | $22,797 | -90.4% | 14,338 | -62.2% | 0.00% | – |
| Q4 2022 | $236,291 | +242.5% | 37,928 | +249.9% | 0.00% | – |
| Q2 2022 | $69,000 | -89.2% | 10,840 | -52.3% | 0.00% | -100.0% |
| Q1 2021 | $637,000 | +111.6% | 22,721 | +96.5% | 0.00% | – |
| Q4 2020 | $301,000 | -9.1% | 11,560 | +30.0% | 0.00% | – |
| Q3 2020 | $331,000 | +29.8% | 8,893 | +79.1% | 0.00% | – |
| Q2 2020 | $255,000 | +7.6% | 4,965 | +24.9% | 0.00% | – |
| Q4 2019 | $237,000 | +0.9% | 3,975 | -21.4% | 0.00% | – |
| Q2 2019 | $235,000 | -20.9% | 5,060 | -24.5% | 0.00% | – |
| Q3 2018 | $297,000 | +23.2% | 6,699 | +28.8% | 0.00% | -100.0% |
| Q2 2017 | $241,000 | – | 5,200 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 2,629,835 | $116,685,000 | 25.08% |
| Aviva Holdings Ltd. | 1,200,100 | $53,248,000 | 14.21% |
| Boxer Capital, LLC | 1,375,000 | $61,009,000 | 6.77% |
| BB BIOTECH AG | 3,282,964 | $145,665,000 | 3.86% |
| Rhenman & Partners Asset Management AB | 353,961 | $15,705,000 | 1.57% |
| PFM Health Sciences, LP | 1,970,134 | $87,415,000 | 1.28% |
| Bellevue Group AG | 391,852 | $17,386,000 | 1.10% |
| Pentwater Capital Management LP | 2,351,500 | $104,336,000 | 0.88% |
| Partner Investment Management, L.P. | 25,440 | $1,129,000 | 0.86% |
| SABBY MANAGEMENT, LLC | 100,369 | $4,453,000 | 0.57% |